

# T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/TAE0A46715EEN.html>

Date: November 2018

Pages: 77

Price: US\$ 3,500.00 (Single User License)

ID: TAE0A46715EEN

## Abstracts

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2018

### SUMMARY

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 21 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD4 - Pipeline Review, H2 2018, outlays comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It regulates T-cell activation. It induces the aggregation of lipid rafts. It acts as a receptor for human immunodeficiency virus-1, human Herpes virus 7/HHV-7. It is down regulated by HIV-1 Vpu. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 1, 6 and 3 respectively.

Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease, Immunology, Central Nervous System, Cardiovascular and Gastrointestinal which include indications Human Immunodeficiency Virus (HIV)

Infections (AIDS), Systemic Lupus Erythematosus, Autoimmune Disorders, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Encephalitis, Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Malaria, Myocarditis, Psoriasis, Severe Acute Respiratory Syndrome (SARS), Simplexvirus (HSV) Infections, Smallpox and West Nile Virus Infections.

Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)

The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects

The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA),

route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Overview

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) -

Companies Involved in Therapeutics Development

Biotest AG

Bristol-Myers Squibb Co

CEL-SCI Corp

Evotec AG

Immupharma Plc

TaiMed Biologics Inc

United Biomedical Inc

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles

Antibodies to Inhibit CD4 for HIV-1 Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Inhibit CD4 and gp120 for HIV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target CD4 and gp120 for HIV-1 Infection - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
CEL-1000 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Drugs to Target CD4 for Autoimmune Disorders - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
forigerimod acetate - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
ibalizumab - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
M-48U1 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
MAX-16H5 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Monoclonal Antibody to Inhibit CD4 for HIV-1 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
N-6 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress

**Recombinant Protein to Inhibit CD4 for HIV Infections - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Recombinant Proteins to Inhibit CD4 for Immunoinflammatory Disorders - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**SAR-441236 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Small Molecules to Activate CD4 for HIV - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**TMB-360 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**TMB-365 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**tregalizumab - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**UB-421 - Drug Profile**

Product Description

Mechanism Of Action

R&amp;D Progress

**T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Products****T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) -**

## Discontinued Products

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones

## Featured News & Press Releases

Oct 30, 2018: Trogarzo phase III data analysis presented at HIV Drug Therapy Glasgow 2018: Patients not achieving primary endpoint at day 7 experienced clinical benefit by end of study

Oct 29, 2018: United States Department of Health and Human Services publishes new HIV Treatment guidelines including Trogarzo

Oct 03, 2018: Pharmacokinetic profile of Trogarzo presented at IDWeek

Aug 28, 2018: Theratechnologies files marketing authorization application for Trogarzo in Europe

Aug 15, 2018: New HIV therapy reduces virus, boosts immunity in drug-resistant patients

Aug 15, 2018: the New England Journal of Medicine publishes two articles about Trogarzo

Jul 31, 2018: European Medicines Agency confirms accelerated assessment procedure for Trogarzo

Jul 25, 2018: Trogarzo included in most recent treatment guidelines issued by International Antiviral Society

Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data

May 29, 2018: Further Analysis from its Pivotal Phase III Trial of Lupuzor in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort

May 23, 2018: Theratechnologies Announces Agreement With AIDS Drug Assistance Program (ADAP) for Trogarzo

May 16, 2018: Theratechnologies Provides Update on Trogarzo (Ibalizumab-Uiyk) Injection Prescriptions and Reimbursement Status

Apr 30, 2018: Theratechnologies Announces that Trogarzo (Ibalizumab-Uiyk) Injection is Now Available in the U.S.

Apr 30, 2018: Theratechnologies to Present Data on Trogarzo at Bloom Burton Healthcare Investor Conference

Apr 24, 2018: Theratechnologies to Seek Regulatory Approval of Trogarzo (ibalizumab) in Europe

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Biotest AG, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by CEL-SCI Corp, H2 2018

Pipeline by Evotec AG, H2 2018

Pipeline by Immupharma Plc, H2 2018

Pipeline by TaiMed Biologics Inc, H2 2018

Pipeline by United Biomedical Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

Biotest AG

Bristol-Myers Squibb Co

CEL-SCI Corp

Evotec AG

Immupharma Plc

TaiMed Biologics Inc

United Biomedical Inc

## I would like to order

Product name: T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/TAE0A46715EEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TAE0A46715EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

